Cancer is a disorder resulting from autonomous, uncontrolled cell growth and differentiation, and with malignant behavior, is capable of invasion and metastasis. Carcinogenesis is initiated by non-lethal genetic damage, followed by a multi-step process involving both phenotypic and genetic changes. Regulatory genes such as the proto- oncogenes, the tumor suppressor genes, and genes regulating apoptosis are important targets of genetic damage, as well as the DNA repair genes. Mutational damage to these genes will result in activation or inactivation of the functions of their gene products, resulting in uncontrolled proliferation with abnormal differentiation and acquisition of the capability for invasion or metastasis. Because of our longstanding interests in proteins, we are exploring the protein changes that occur in human cancer. Initially, we collaborated with the Department of Pathology, Phramongkutklao Hospital, Bangkok to analyze changes in protein in human cancer tissues, using surgical specimens of tumor tissue and normal tissue, characterized in terms of pathology. Our group was the first research group in Thailand to use the proteomic approach in 1997, at that time using two-dimensional gel electrophoresis to compare the proteome patterns (or the total protein present at any tissue at any given time) between normal and cancer tissue. Thus, study of thyroid disease demonstrated increased expression of certain proteins, such as cathepsin B and prohibitin, in neoplastic thyroid diseases...

Our early studies on genetic diseases, since 1987 and earlier, focused on the hemoglobinopathies, which occur frequently in Thailand and consist of two types. Thalassemia results from lack or decreased synthesis of one or more globin chains, while abnormal hemoglobins consist of mutations altering the amino acid sequence of globin chain(s). However, as research in the hemoglobinopathies developed in Thailand, we shifted our interest to Inborn Errors of Metabolism, which can cause severe clinical manifestations, such as mental retardation or developmental abnormalities. Generally, inborn errors arise from deficiencies in enzymes of various metabolic pathways, such as the urea cycle, pathways for degradation or synthesis of specific amino acids, or mucopolysaccharide degradation. Such disorders may be due to mutations leading to dysfunctional or poorly functioning enzyme or may result from lowered expression or absence of these enzymes. Such enzyme deficiencies are typically detected by an accumulation of the substrate of the enzyme reaction and/or a decrease in the level of metabolites, which occur after the enzyme reaction. Typically, each inborn error of metabolism occurs with low frequency, but there are many defects, so cumulatively, inborn errors of metabolism are significant problems. In many cases, the devastating effects can be avoided through proper treatment, such as in phenylketonuria, which may be treated with diets low in phenylalanine. So, it is important to...

Name: Voraratt Champattanachai Office address: Research Laboratory of Biochemistry, Chulabhorn Research Institute, 54 Kamphaeng Phet 6 Talat Bang Khen, Lak Si, Bangkok 10210, Thailand Tel: +662-5538555 ext. 3230, 3232 Fax: +662-5538560 Positions: Research Scientist II, Research Laboratory of Biochemistry, Chulabhorn Research Institute E-mail: [email protected] Website: – Research Interests 1. Cancer Biomarkers 2. Cancer immunotherapy 3. Human genetic diseases Education and Degrees: B.Sc. (Biology), Kasetsart University, Thailand M.S. (Biochemistry), Mahidol University, Thailand Ph.D. (Cell Biology), The University of Alabama at Birmingham, U.S.A Academic Positions Research Scientist II, Chulabhorn Research Institute, 2018-present Research Scientist I, Chulabhorn Research Institute, 2014-2018 Research Scientist, Chulabhorn Research Institute, 1993-2014 Guest Lecturer, Chulabhorn Graduate Institute, 2002-present Professional Societies (If any) Member, The Science Society of Thailand under the Patronage of H.M. the King, 1998-present Member, American Association of Anatomists, U.S.A., 2003-2007 Committee, Protein Society of Thailand, 2009-present Steering committee, Asian Community of Glycoscience and Glycotechnology, (ACGG), Japan, 2011-2020 Member, Genetic Society of Thailand, Thailand, 2018-present Editorial board of Molecular Medicine Reports (Spandidos Publications) and Oncology Reports (Spandidos Publications), 2019-present Fellowships Thai Government Scholarship (Ministry of Science and Technology, Thailand), 2002 International Awards & Honours Local Awards & Honours 1st Poster Presentation Award, 11th National Cancer Institute conference, 2012 Royal Decorations (If any) ORCID iD (if available): http://orcid.org/0000-0002-4287-318x Publications 1. Effects of gentamicin inducing read...

Name: Miss Khajeelak Chiablaem Office address: Research Laboratory of Biochemistry, Chulabhorn Research Institute, 54 Kamphaeng Phet 6 Talat Bang Khen, Lak Si, Bangkok 10210, Thailand Tel: +662-5538555 (ext. 3238) E-mail: [email protected] Positions: Research Scientist, Research Laboratory of Biochemistry, Chulabhorn Research Institute Research Interests 1. Cancer bioinformatics 2. Cancer invasion and metastasis 3. Cancer and alternative medicine Education and Degrees: • B.Sc. (Biology), Chiang Mai University, Thailand • M.Sc. (Technoprenership and Innovation Management), Chulalongkorn University, Thailand • Ph.D. Candidate (Translational Medicine), Mahidol University, Thailand ORCID ID: http://orcid.org/0000-0002-9139-4695 Publications 1. Shiao MS, Chiablaem K, Charoensawan V, Ngamphaiboon N, Jinawath N. Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type. Front Genet. 2018 Aug 15;9:309. doi: 10.3389/fgene.2018.00309. PMID: 30158952; PMCID: PMC6104394. 2. Samutprasert P, Chiablaem K, Teeraseranee C, Phaiyarin P, Pukfukdee P, Pienpinijtham P, Svasti J, Palaga T, Lirdprapamongkol K, Wanichwecharungruang S. Epigallocatechin gallate-zinc oxide co-crystalline nanoparticles as an anticancer drug that is non-toxic to normal cells. RSC Adv. 2018 Feb 15;8(14):7369-7376. doi: 10.1039/c7ra10997k. PMID: 35539101; PMCID: PMC9078484. 3. Kuljittichanok D, Diskul-Na-Ayudthaya P, Weeraphan C, Chokchaichamnankit D, Chiablaem K, Lirdprapamongkol K, Svasti J, Srisomsap C. Effect of Derris scandens extract on a human hepatocellular carcinoma cell line. Oncol Lett. 2018 Aug;16(2):1943-1952. doi: 10.3892/ol.2018.8824. Epub 2018 May 29. PMID: 30034552; PMCID: PMC6053636. 4. Subhasitanont P, Chokchaichamnankit D, Chiablaem...